Avance Clinical Awarded Frost & Sullivan 2021 Asia-Pacific CRO Best Practices Award for Customer Value Leadership
ADELAIDE, AUS, Aug 10, 2021 - (ACN Newswire) - Avance Clinical, the largest premium Australian CRO for international biotechs, has been awarded the prestigious Frost & Sullivan 2021 Asia-Pacific CRO Customer Value Leadership Award, the second consecutive Asia-Pacific (APAC) CRO Best Practices Award for the company from Frost & Sullivan.
Avance Clinical is an Australian owned Contract Research Organisation (CRO) that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 24 years.
Frost & Sullivan says the Asia-Pacific's CRO market value, currently at $6.01 billion, is estimated to reach nearly $11.04 billion in 2026, growing at a compound annual rate of 12.2%.
"The region is becoming the go-to research and development market, with China, Japan, Australia, and South Korea in the lead, accounting for 16% of the APAC clinical CRO market in 2020," according to Supriya Lala Kundu, Best Practices Research Analyst, Frost & Sullivan.
This is the second Frost & Sullivan award for Avance Clinical, which has seen rapid growth in the APAC region over the past year.
Avance Clinical's CEO Yvonne Lungershausen commended her team of more than 150 clinical trial specialists across Australia and New Zealand.
"We have shown, with our 89% growth and repeat business rate of greater than 70% that our focus on gold standard technology paired with solution-orientated clinical experts is the mix clients require in this fast moving, competitive and high-stakes sector. Avance Clinical is immensely proud of this acknowledgment. This award is real recognition of our successful approach to delivering value to our customers.
Clients talk about the advantage of Australia's financial tax rebate incentive of almost 50% on clinical trial spend - but I believe the real benefit is in saving time. Our biotech clients can leverage fast start up with the Australian regulatory process and obtain early clinical data without first acquiring their in-country IND. The net effect for our clients is they can speed up their clinical program by getting into the clinic up to a year earlier than anywhere else in the world, and saving significant associated costs."
Avance Clinical specialises in supporting biotech companies with their early phase clinical trials having conducted over 195 early phase (Phase 1 and 2) trials in the past 5 years involving over 10,000 participants across 105 therapeutic indications.
According to Supriya Lala Kundu, Best Practices Research Analyst, Frost & Sullivan:
"Avance Clinical has grown rapidly over the past year since our last analyst review, including further expansions of clinical services across Australia and New Zealand. Its impressive repeat business rate of greater than 70% speaks to its customer value and reputation in the sector and is a key factor in the 2021 award selection.
Avance Clinical's clients are international biotech companies primarily from the United States, United Kingdom, Japan, China, South Korea, Taiwan, France, and Germany. These clients are seeking a premium CRO with the same experience and advanced technology platforms offered by the major global CROs, but with an agile and customer focused approach to clinical management in Australia and New Zealand.
The company offers best-in-class technologies from leaders such as Oracle, Medidata and Medrio, enabling rapid high-quality data management accepted by all the major regulatory authorities globally, with a highly experienced team of more than 150 clinical specialists, with deep experience across more than 105 indications.
The company's accreditation as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) has allowed it to expand into clinical trials for vaccines and GMO therapies.
Australia's reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials."
Key Frost & Sullivan analyst findings around the Avance Clinical offering include:
- Financial Performance: Strong overall financial performance is achieved in terms of revenues, revenue growth, operating margin, and other key financial metrics
- Customer Acquisition: Customer-facing processes support efficient and consistent new customer acquisition while enhancing customer retention
- Operational Efficiency: Company staff performs assigned tasks productively, quickly, and to a high-quality standard
- Growth Potential: Growth is fostered by a strong customer focus that strengthens the brand and reinforces customer loyalty
- Human Capital: Commitment to quality and to customers characterize the company culture, which in turn enhances employee morale and retention
- Price/Performance Value: Products or services provide the best value for the price compared to similar market offerings
- Customer Purchase Experience: Quality of the purchase experience assures customers that they are buying the optimal solution for addressing their unique needs and constraints
- Customer Ownership Experience: Customers proudly own the company's product or service and have a positive experience throughout the life of the product or service
- Customer Service Experience: Customer service is accessible, fast, stress-free, and high quality
- Brand Equity: Customers perceive the brand positively and exhibit high brand loyalty
Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/
For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/
About Avance Clinical www.avancecro.com
Avance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs for 24 years. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.
Frost & Sullivan awards
Avance Clinical is a Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award recipient and a 2021 Asia-Pacific CRO Customer Value Leadership Award recipient.
Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.
Avance Clinical delivers customised solutions designed around specific client needs rather than a one size fits all approach. With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.
As a company, Avance Clinical has focused on state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
DOCOMO to Conduct Open RAN Field Trials with Ooredoo, Smart and StarHub
Feb 27, 2024 19:53 JST
CleverTap partners with Zoomcar to drive customer engagement on their app
Feb 27, 2024 18:00 JST
NEC Selected by NTT DOCOMO as a Virtualized Radio Access Network (vRAN) Vendor
Feb 26, 2024 17:54 JST
Fujitsu and Celonis Expand Strategic Global Partnership
Feb 26, 2024 15:40 JST
Mitsubishi Corporation's Sale of Exportadora de Sal, S.A. de C.V., a Salt Production Company in Mexico
Feb 26, 2024 14:29 JST
'MMVO,' Mazda's Production Base in Mexico Marks its 10th Anniversary
Feb 26, 2024 14:00 JST
Mitsubishi Electric Building Solutions to Supply Elevators and Escalators for New Capital Relocation Project in Indonesia
Feb 26, 2024 11:00 JST
Clear Mobitel Successfully Deploys NEC 5G SA Cloud Native Core Network to Accelerate the Adoption of Innovative 5G Solutions in the UK and the Channel Islands
Feb 22, 2024 17:13 JST
NEC UPF Achieves Industry-Leading High Performance in 5G Core Networks, reaching 1.3Tbps Throughput
Feb 22, 2024 16:10 JST
DOCOMO and NTT Expand 6G Collaborations with SK Telecom and Rohde & Schwarz
Feb 22, 2024 15:33 JST
Successful demonstration of computing and mobile networks convergence to provide diverse services in the 6G era
Feb 22, 2024 13:18 JST
Fujitsu introduces "Uvance Wayfinders", expanded and strengthened consulting capabilities to deliver cross-industry business value
Feb 22, 2024 12:05 JST
Fujitsu delivers new supercomputer system to Japan Meteorological Agency to improve prediction accuracy for typhoons and torrential rain
Feb 21, 2024 16:38 JST
MHI Group Presents "Best Innovation 2023" Awards for Activities that Contribute to Protecting the Environment
Feb 21, 2024 16:28 JST
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
Feb 21, 2024 15:26 JST
NEC, Arm, Qualcomm, Red Hat, and Hewlett Packard Enterprise demonstrate Open vRAN and 5G Core UPF using Arm-based CPUs
Feb 21, 2024 14:09 JST
NEC launches new User Plane Function (UPF) product for telecom operators, aiming to achieve networks for the Beyond 5G/6G era
Feb 21, 2024 11:33 JST
TANAKA to Provide Pure Gold, Pure Silver, and Pure Bronze Medals for the Tokyo Marathon 2024
Feb 21, 2024 04:00 JST
Fujitsu collaborates with QuTech in development of new technology for freezing electronics to control diamond spin qubits
Feb 20, 2024 21:28 JST
NTT DOCOMO and SK Telecom Release White Paper on Base Station Equipment Utilizing Virtualization Technology
Feb 20, 2024 15:32 JST